Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone
Brief Summary: This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and safety of patiromer and the long term use of patiromer.


Options:
A: Arm Label: Stratum 1: 8.4 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 1: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 16.8 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 25.2 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Arm Label: Stratum 2: 33.6 g/d patiromer; Type: EXPERIMENTAL; Interventions: Drug: patiromer, Drug: losartan, Drug: spironolactone | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 8.4 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 1: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 25.2 g/d patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): Stratum 1: 16.8 g/d patiromer, Stratum 1: 25.2 g/d patiromer, Stratum 1: 8.4 g/d patiromer, Stratum 2: 16.8 g/d patiromer, Stratum 2: 25.2 g/d patiromer, Stratum 2: 33.6 g/d patiromer
B: Arm Label: Sodium zirconium cyclosilicate 10 g three times daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sodium zirconium cyclosilicate 5 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 10 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Arm Label: Sodium zirconium cyclosilicate 15 g once daily; Type: EXPERIMENTAL; Interventions: Drug: Sodium zirconium cyclosilicate | Intervention Type: DRUG; Name: Sodium zirconium cyclosilicate; Assigned to Arm(s): Sodium zirconium cyclosilicate 10 g once daily, Sodium zirconium cyclosilicate 10 g three times daily, Sodium zirconium cyclosilicate 15 g once daily, Sodium zirconium cyclosilicate 5 g once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo once daily
C: Arm Label: Zirconium silicate (acute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (acute phase) | Arm Label: Placebo (acute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (acute phase) | Arm Label: Zirconium silicate (subacute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (subacute phase) | Arm Label: Placebo (subacute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ( subacute phase) | Intervention Type: DRUG; Name: Zirconium silicate (acute phase); Assigned to Arm(s): Zirconium silicate (acute phase) | Intervention Type: DRUG; Name: Zirconium silicate (subacute phase); Assigned to Arm(s): Zirconium silicate (subacute phase) | Intervention Type: DRUG; Name: Placebo (acute phase); Assigned to Arm(s): Placebo (acute phase) | Intervention Type: DRUG; Name: Placebo ( subacute phase); Assigned to Arm(s): Placebo (subacute phase)
D: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A